Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy

Current Medicinal Chemistry

Volumn 15, Issue 12, 2008, Pages 1229-1235

  Stratta, Piero ^a   Canavese, Caterina ^a   Aime, Silvo ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Contrast agents; Gadodiamide; Gadolinium Chelates; Macrophages; Procollagen

Indexed keywords

ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ZINC; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FIBROSIS; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PSEUDOHYPOCALCEMIA; PUBLIC HEALTH; RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT CONTRAINDICATION; UREMIA; ZINC BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; KIDNEY DISEASE; RISK; SKIN DISEASE;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; RENAL DIALYSIS; RISK; SKIN DISEASES;

EID: 45849084241     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986708784310396     Document Type: Review

References (25)

1. Cowper, S.E.; Robin, H.S.; Steinberg, S.M.; Su, L.D.; Gupta, S.; LeBoit, P.E. Lancet, 2000, 356, 1000.
2. Grobner, T. Nephrol. Dial. Transplant., 2006, 21, 1104.
3. Marckmann, P.; Skov, L.; Rossen, K.; Dupont, A.; Damholt, M.B.; Heaf, J.G.; Thomsen, H.S. J.Am. Soc. Nephrol., 2006, 17, 2359.
4. Sadowski, E.A.; Bennett, L.K.; Chan, M.R.; Wentland, A.L.; Garrett, A.L.; Garrett, R.W.; Djamali, A Radiology, 2007, 243, 148.
5. Marckmann, P.; Skov, L.; Rossen, K.; Goya, J.H.; Thomsen, H.S. Nephrol. Dial.Transplant., 2007, 22, 3174.
6. Broome, D.R.; Girguis, M.S.; Baron, P.W.; Cottrell, A.C.; Kjellin, I.; Kirk, G.A.M. Am. J. Roentgenol., 2007, 188, 586
7. LeBoit, P.E. Arch. Dermatol., 2003, 139, 928.
8. Grobner, T.; Prischl, F.C. Kidney Int., 2007, 72, 260.
9. Boyd, A.S.; Zic, J.A.; Abraham, J.L J. Am. Acad. Dermatol., 2007, 56, 27.
10. High, W.A.; Ayers, R.A.; Cowper, S.E. Am. Acad. Dermatol., 2007, 56, 710.
11. U.S. Food and Drug Administration (FDA). Information for healthcare professionals: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI) (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance). Rockville, MD: U.S. Food and Drug Administration; June 2006, December 2006, February 2007, May2007. Available at: http://www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm.
12. European Agency for the Evaluation of Medicinal Products (EMEA) Gadolinium- containing MRI contrast agent and nephrogenic systemic fibrosis, February 2007Available at http://www.ismrm.org/special/ EMEA1.pdf, http://www.ismrm.org/special/EMEA2.pdf, http://www.ismrm.org/ special/EMEA3.pdf.
13. ACR guidance Document for safe MR practices 2007, available at http://www.acr.org/s_acr/bin.asp?CID=3260&DID= 25812&DOC=FILE.PDF
14. Cabella, C.; Crich, S.G.; Corpillo, D.; Barge, A.; Ghirelli, C.; Bruno, E.; Lorusso, V.; Uggeri, F.; Aime, S. Contrast. Medial. Mol. Imaging, 2006, 1, 23.
15. Idee, J.; Port, M.; Raynal, I.; Schaefer, M.; Le Greneur, S.; Corot, C. Fundam. Clin. Pharmacol., 2006, 20, 563.
16. White, G.W.; Gibby, W.A.; Tweedle, M.F. Invest. Radiol., 2006, 41, 272.
17. Canavese, C.; Mereu, C.; Nordio, M.; Sabbioni, E.; Aime, S. Curr. Med. Chem., 2005, 12, 1631.
18. Okada, S.; Katagiri, K.; Kumazaki, T.; Yokoyama, H. Acta Radiol., 2001, 42, 339.
19. Cowper, S.E. Nephrogenic fibrosing dermopathy NFD/NSF Website. 2001-2007. Available at: http://www.icnfdr.org.
20. Deo, A.; Fogel, M.; Cowper, S.E. Clin. J. Am. Soc. Nephrol., 2007, 2, 264.
21. Perazella, M.A. Clin. J. Am. Soc. Nephrol., 2007, 2, 200.
22. Evans, C.H.; Drouven, B.J. Biochem. J., 1983, 213, 751.
23. Scott, T.L. J. Biol. Chem., 1984, 259, 4035.
24. Drouven, B.J.; Evans, C.H. J. Biol. Chem., 1986, 261, 11792.
25. Ortonne, N.; Lipsker, D.; Chantrel, F.; Boehm, N.; Grosshans, E.; Cribier, B. Br. J. Dermatol., 2004, 150, 1050.